Justin Moser

5PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

Rebecca Porter, Bruno Bockorny, Bradley R Corr

|Jun 18, 2025
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies.

Jay Jacoby, Deva Mahalingam, Angela Alistar

|Aug 03, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).

Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani

|Jul 15, 2022
The Mechanisms of Action of Tumor Treating Fields.

Justin C Moser, Ellaine Salvador, Karina Deniz

|May 20, 2020
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.

Kelsey Baron, Justin C Moser, Shiven Patel

Pageof 1

Frequent Collaborators

1 joint publications

Ellaine Salvador

1 joint publications

Jack Tuszynski

1 joint publications

Chirag B Patel

1 joint publications

Michael Story